Liu Yuming, Zeng Dehua, Gao Yunzhen
Department of Anesthesiology, MengChao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China.
Department of Pathology, The 900, Hospital of Joint Logistic Support Force, PLA, Fuzhou, 350025, China.
Discov Oncol. 2024 May 12;15(1):158. doi: 10.1007/s12672-024-01005-0.
Clear cell renal cell carcinoma (ccRCC), with high mortality and poor prognosis, is the most common type of renal malignancy. It is necessary to identify new biomarkers that can serve as indicators for the detection of ccRCC at its early stages. In this study, we analyzed the role of classical zinc finger protein 692 (ZNF692) in ccRCC using datasets from The Cancer Genome Atlas (TCGA) and Single Cell Portal and immunohistochemical (IHC) staining of a tissue-microarray, and analyzed the function of ZNF692 in ccRCC cells. The analyses indicated that ZNF692 was upregulated in ccRCC samples compared with normal or paracancerous control samples (P < 0.001) and that the expression of this gene was linked to poor overall survival (HR = 2.1, P < 0.0001). The knockdown of ZNF692 inhibited the proliferation and migration of ccRCC cells by target GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2), and transmembrane 9 superfamily member 2 (TM9SF2)). T, B, proximal, and collecting tubule cells are the dominant cell types in normal kidney tissue where ZNF692 is expressed. In addition, immune checkpoint blockade (ICB) therapy dramatically changed the expression patterns of ZNF692. Collectively, these data indicate that ZNF692 may serve as prognosis, and as a potential indicator of the response to ICB therapy, a possibility needs to be verified by a case‒control study.
透明细胞肾细胞癌（ccRCC）是最常见的肾脏恶性肿瘤类型，死亡率高且预后较差。有必要鉴定出可作为ccRCC早期检测指标的新生物标志物。在本研究中，我们使用来自癌症基因组图谱（TCGA）和单细胞门户的数据集以及组织芯片的免疫组织化学（IHC）染色，分析了经典锌指蛋白692（ZNF692）在ccRCC中的作用，并分析了ZNF692在ccRCC细胞中的功能。分析表明，与正常或癌旁对照样本相比，ZNF692在ccRCC样本中上调（P < 0.001），并且该基因的表达与总体生存率低相关（HR = 2.1，P < 0.0001）。敲低ZNF692通过靶向GTP酶激活蛋白（SH3结构域）结合蛋白2（G3BP2）和跨膜9超家族成员2（TM9SF2）抑制ccRCC细胞的增殖和迁移。T、B、近端和集合管细胞是正常肾组织中表达ZNF692的主要细胞类型。此外，免疫检查点阻断（ICB）治疗显著改变了ZNF692的表达模式。总体而言，这些数据表明ZNF692可能作为预后指标，以及作为ICB治疗反应的潜在指标，这一可能性需要通过病例对照研究来验证。
